hydralazine and valsartan

hydralazine has been researched along with valsartan in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (42.86)	29.6817
2010's	11 (52.38)	24.3611
2020's	1 (4.76)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Akasaka, T; Imanishi, T; Kobayashi, K	1
Akasaka, T; Goto, M; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Yoshida, K	1
Fukushima, H; Kobayashi, N; Matsuoka, H; Ohno, T; Yoshida, K	1
Azuma, K; Hirose, T; Ikeda, F; Kawamori, R; Mita, T; Ogihara, T; Otsuka, A; Tanaka, Y; Toyofuku, Y; Watada, H	1
Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Shintaku, H; Tokutomi, Y; Yamamoto, E; Yamashita, T	1
Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL	1
Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E	1
Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I	1
Aderibigbe, A; Anisiuba, BC; Ba, SA; Boombhi, HJ; Ijoma, CK; Kamdem, MK; Kaptue, J; Kingue, S; Kolo, PM; Lemogoum, D; M'buyamba-Kabangu, JR; Mipinda, JB; Ndiaye, MB; Odili, AN; Omotoso, BA; Richart, T; Staessen, JA; Thijs, L; Ulasi, II	1
Cao, YM; Gao, WH; Hu, JW; Lv, YB; Mu, JJ; Wang, Y; Xie, BQ; Yan, DY; Yuan, ZY; Zheng, WL	1
Adhyaru, B; Raj, L	1
Butler, J; Hamo, CE; Papadimitriou, L	1
Asselin, CY; Cheung, D; Czaykowski, P; Dingman, B; Edel, A; Goyal, V; Jassal, DS; Kim, E; Mittal, I; Mozolevska, V; Ravandi, A; Schwartz, A; Shaikh, B; Singal, PK; Thliveris, J	1
Adams, KF; Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Giblin, EM; Hernandez, AF; Hill, L; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB	1
Heidenreich, PA; Kohsaka, S; Lewis, EF; Sandhu, AT; Turakhia, MP	1

Reviews

3 review(s) available for hydralazine and valsartan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). Postgraduate medical journal, 2016, Volume: 92, Issue:1094 Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents	2016
Heart Failure Guidelines on Pharmacotherapy. Handbook of experimental pharmacology, 2017, Volume: 243 Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Nitrates; Practice Guidelines as Topic; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents	2017

Trials

1 trial(s) available for hydralazine and valsartan

Article	Year
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial. Blood pressure, 2011, Volume: 20, Issue:5 Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Drug Combinations; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Middle Aged; Research Design; Risk Factors; Tetrazoles; Valine; Valsartan	2011

Article

Year

Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.

Blood pressure, 2011, Volume: 20, Issue:5

Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Drug Combinations; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Methyldopa; Middle Aged; Research Design; Risk Factors; Tetrazoles; Valine; Valsartan

2011

Other Studies

17 other study(ies) available for hydralazine and valsartan

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model. Hypertension research : official journal of the Japanese Society of Hypertension, 2006, Volume: 29, Issue:6 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cellular Senescence; Endothelium, Vascular; Hydralazine; Male; Rats; Rats, Wistar; Stem Cells; Telomerase; Tetrazoles; Valine; Valsartan; Vasodilator Agents	2006
Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:6 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Catheterization; Cyclic N-Oxides; Disease Models, Animal; Hydralazine; Male; Nitric Oxide; Oxidants; Oxidative Stress; Rabbits; Spin Labels; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents; Vasodilator Agents	2006
Cardioprotective effect of angiotensin II type 1 receptor antagonist associated with bradykinin-endothelial nitric oxide synthase and oxidative stress in Dahl salt-sensitive hypertensive rats. Journal of hypertension, 2007, Volume: 25, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Hydralazine; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Pyridines; Rats; Rats, Inbred Dahl; RNA, Messenger; Tetrazoles; Valine; Valsartan	2007
Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats. Endocrine journal, 2007, Volume: 54, Issue:4 Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blood Pressure; Cell Adhesion; Deoxyguanosine; Endothelial Cells; Hydralazine; Hypertension; Male; Monocytes; Rats; Rats, Inbred SHR; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan	2007
Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:12 Topics: Acetophenones; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; Biopterins; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Endothelium, Vascular; Heart Failure, Diastolic; Hydralazine; Hypertension; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase Type III; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Signal Transduction; Sodium Chloride, Dietary; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation	2007
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. Journal of hypertension, 2008, Volume: 26, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Endomyocardial Fibrosis; Endothelium, Vascular; Hydralazine; Hypertension; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Tetrazoles; Tyrosine; Valine; Valsartan	2008
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. Stroke, 2008, Volume: 39, Issue:11 Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressure; Cerebral Cortex; Enzyme Activation; Enzyme Inhibitors; Humans; Hydralazine; Hypertension; Inflammation; Male; NADPH Oxidases; Neurons; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Sodium Chloride; Stroke; Tetrazoles; Valine; Valsartan	2008
Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling. American journal of hypertension, 2011, Volume: 24, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Arteries; Blood Vessels; Disease Models, Animal; Hydralazine; Hypertension; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neointima; Oxidative Stress; Renin; Tetrazoles; Valine; Valsartan	2011
Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet. Kidney & blood pressure research, 2015, Volume: 40, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diet; Enalapril; Hydralazine; Kidney; Male; Monoamine Oxidase; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Sodium Chloride, Dietary; Valsartan	2015
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction. American journal of physiology. Heart and circulatory physiology, 2019, 03-01, Volume: 316, Issue:3 Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bevacizumab; Cardiotoxicity; Fumarates; Hydralazine; Male; Mice; Mice, Inbred C57BL; Perindopril; Renin-Angiotensin System; Sunitinib; Valsartan; Ventricular Dysfunction	2019
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). The American journal of cardiology, 2019, 12-15, Volume: 124, Issue:12 Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black or African American; Cohort Studies; Drug Combinations; Drug Utilization; Female; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Neprilysin; Prognosis; Registries; Retrospective Studies; Risk Assessment; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan	2019
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. JAMA cardiology, 2022, 02-01, Volume: 7, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Nitrates; Practice Guidelines as Topic; Quality of Health Care; Stroke Volume; United States; United States Department of Veterans Affairs; Valsartan; Veterans	2022